anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Gozetotide
Trial phase: Phase 2
SMILES: O=C(O)CCc1ccc(O)c(CN(CCN(CC(=O)O)Cc2cc(CCC(=O)NCCCCCC(=O)NCCCCC(NC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)O)c1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Patients with suspected prostate cancer who have at least one PI-RADS 5 lesion, or at least one PI-RADS 4 lesion and PSA ≥10 nanograms/milliliter (ng/mL), on standard of care mpMRI of the prostate, who are scheduled for biopsy or radical prostatectomy

68Ga PSMA-11 injection: Injection of 68Ga PSMA-11

Positron Emission Tomography/Computed Tomography: PET/CT scan after 68Ga PSMA-11 injection
Eligibility criteria:
Inclusion Criteria:

Patients with suspected prostate cancer (e.g., abnormal digital rectal exam, elevated and/or rising PSA) as determined by referring physician
Patients must have had a diagnostic, standard of care mpMRI of the prostate with at least one lesion with a PI-RADS v2.1 score ≥ 4
In men with PI-RADS v2.1 score 4, PSA should be ≥ 10 ng/mL. In men with at least one PI-RADS v2.1 score 5 lesion, there is no restriction on PSA level.
Patients must be scheduled for biopsy or radical prostatectomy
Patients should not have had any type of curative or palliative therapy for prostate cancer before enrolling in the study
Patients must be medically stable as judged by the patient's physician
Patients must be able to lie still for a total of 60 minutes for the PET/CT scans
Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

Patients who have had a prior prostatectomy or radiotherapy for prostate cancer cannot participate in the study
Patients who have had a prior biopsy for prostate cancer cannot participate in the study
Patients who have been treated for cancers other than skin cancers
Subjects may not be receiving any other investigational agents for the treatment of the cancer under study
Patients may not weigh more than the maximum weight limit for the PET/CT scanner table (>200 kilograms or 440 pounds)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 68Ga PSMA-11 or other agents used in the study such as gadolinium-based intravenous contrast agent used during the mpMRI
Prior transurethral resection of the prostate (TURP)/benign prostatic hyperplasia (BPH) procedures, including steam/laser therapies
Intervention: Sirolimus
Trial phase: Early Phase 1
ATC code: L01EG04 | L04AA10 | S01XA23
SMILES: COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Sirolimus 1mg orally once a day for 8 weeks

Rapamune: Sirolimus 1mg capsules
Eligibility criteria:
Inclusion Criteria:

Diagnosis of Mild Cognitive Impairment (MCI), Clinical Dementia Rating Scale (CDR)=0.5-1; Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall ≤5% based on age-adjusted normal values, clinician approved
Normal blood cell counts without clinically significant excursions
A Legally Authorized Representative (LAR) if necessary for consent
An LAR or study partner to accompany participant to all visits
Availability for all study visits
Stable dose of AD medications) Donepezil, rivastigmine, memantine, galantamine) for at least 3 months

Exclusion Criteria:

Diabetes (HbA1c≥6.5% or anti-diabetic medications)
History of skin ulcers or poor wound healing
Current tobacco or illicit drug use or alcohol abuse
Use of anti-platelet or anti-coagulant medications other than aspirin
Current medications that affect cytochrome P450 3A4
Immunosuppressant therapy within the last year
Chemotherapy or radiation treatment within the last year
Current or chronic history of liver disease or known hepatic or biliary abnormalities
Current or chronic history of pulmonary disease or abnormal pulse oximetry (<90%)
Chronic heart failure
Pregnancy
Recent history (past 6 months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or transient ischemic attack
significant neurological conditions other than AD
Poorly controlled blood pressure (systolic BP>160, diastolic BP>90mmHg)
Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, and/or psychiatric disease
History of, or Magnetic Resonance Imaging (MRI) positive for any space occupying lesion, including mass effect and/or abnormal intracranial pressure, which would indicate contraindication to lumbar puncture
Intervention: Oxycodone
Trial phase: Phase 1 | Phase 2
ATC code: N02AA05 | N02AA55 | N02AA56 | N02AJ17 | N02AJ18 | N02AJ19
SMILES: COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 13
Group description: Participants who received initial dose of oxycodone 5 mg tablet followed by a 30-minute rest period to allow for onset of medication effect. This rest period will be followed by a standardized set of oculomotor testing for 40 minutes. After the initial testing, a second dose of oxycodone 5 mg tablet will be administered followed by a 30-minute rest period to allow for the onset of the second dose. The second rest period will be followed by a second round of standardized oculomotor testing for 40 minutes.
Eligibility criteria:
Inclusion Criteria:

Participants must be able to consent to participate themselves
Be healthy male or non-pregnant female
Must be able to attend in-person sessions at the Mayo Aerospace Medicine and Vestibular Research Laboratory in Scottsdale, AZ.
Have not used opioids during the preceding 30 days
Prior use of opioids for pain management

Exclusion Criteria:

Women who are pregnant or breastfeeding.
Women who are not practicing an effective form of contraception (condoms, IUD, birth control pill, diaphragm),
Past or current history of drug or substance use.
Significant ocular disorder.
Positive drug test for marijuana, opioids, methamphetamines, cocaine, PCP or other controlled substances.
History of use of psychoactive drugs within the past 30 days.
Subjects with a history of cardiopulmonary disease including but not limited to congestive heart failure, obstructive sleep apnea, restrictive lung disease, COPD, moderate to severe asthma and oxygen dependency.
Subjects currently taking sedatives (including benzodiazepines), muscle relaxants or disassociatives.
Intervention: Garamycin solution
Trial phase: Phase 2
SMILES: CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1.O=S(=O)(O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 183
Group description: At the completion of the subjects surgery but prior to awakening from anesthesia, 80mg of gentamicin in 50 mL of normal saline will be infused into the subject's bladder through the standard-of-care transurethral catheter by the surgeon. The surgeon will then clamp the catheter and label the catheter with the clamping time. The catheter will be clamped to prevent the gentamicin from immediately flowing out of the bladder and thus allow the gentamicin time to have an effect. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.

gentamicin sulfate: Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
Eligibility criteria:
Inclusion Criteria:

Adult women undergoing pelvic organ prolapse surgery and/or stress urinary incontinence surgery with surgical plan for at least 1 cystoscopy and will leave the operating room with a standard-of-care transurethral catheter.
Negative urine culture within 4 weeks or completion of UTI treatment ≥48 hours prior to surgery

Exclusion Criteria:

History of allergic reaction or anaphylaxis to gentamicin sulfate or to sodium metabisulfite (one of the preservatives in the gentamicin sulfate product)
Abnormal intraoperative urinary tract finding (e.g. bladder mass, stone, or fistula)
Intraoperative urinary tract injury
Suppressive recurrent UTI treatment
Chronic indwelling catheter/self-catheterization
Unable to provide informed consent
Severe renal impairment - glomerular filtration rate of less than 30 mL / minute
Current pregnancy
Currently incarcerated
Intervention: Oxycodone
Trial phase: Phase 4
ATC code: N02AA05 | N02AA55 | N02AA56 | N02AJ17 | N02AJ18 | N02AJ19
SMILES: COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 49
Group description: Patients in this opioid group will receive 15 oral opioid tablets (5 mg oxycodone) Patients will also receive 8 "rescue" medications, in the Oxycodone arm will be placebo "rescue" medications.

All participants will also receive the following as part of standard of care:

Oral non-opioid (1000 mg acetaminophen), every 8 hours.
Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.
Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.
Intraoperative education on post-surgical pain management.

Oxycodone: 5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
Eligibility criteria:
Inclusion Criteria:

Males and females
Aged 14-40 years
Scheduled for primary (Anterior cruciate ligament) ACL reconstruction using quadriceps tendon autograft.

Exclusion Criteria:

Revision and/or contralateral ACL reconstruction procedures
Allergies to local anesthetics
Chronic pain medication use
Weight <50 kg, local infections
Known coagulopathies,
Liver dysfunction or renal failure
Intervention: Tobramycin
Trial phase: Phase 4
ATC code: J01GB01 | S01AA12
SMILES: NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: All patients getting vancomycin and tobramycin to see serum concentration after 24hrs in knee drain and serum levels.

Vancomyscin: Everyone gets the vancomyscin powder.

Tobramycin Powder: Everyone gets tobramycin powder.
Eligibility criteria:
Inclusion Criteria:

Age over 18
Total knee arthroplasty for primary osteoarthritis. Primary diagnosis of knee osteoarthritis

Exclusion Criteria:

Diminished mental capacity
Vancomycin allergy
Tobramycin allergy
Chronic kidney disease stage III and stage IV
Intervention: Hydroxychloroquine Sulfate
Trial phase: Phase 2 | Phase 3
SMILES: CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 407
Group description: Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days

Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
Eligibility criteria:
Inclusion Criteria:

Men or women 18 to 80 years of age inclusive, at the time of signing the informed consent
Willing and able to provide informed consent

Had a close contact of a person (index) with known PCR-confirmed SARS-CoV-2 infection or who is currently being assessed for COVID-19. Close contact defined as:

Household contact (i.e., residing with the index case in the 14 days prior to index diagnosis)
Medical staff, first responders, or other care persons who cared for the index case without personal protection (mask and gloves)
Less than 4 days since last exposure (close contact with a person with SARS-CoV-2 infection) to the index case
Body weight < 100 kg (self-reported)
Access to device and internet for Telehealth visits

Exclusion Criteria:

Known hypersensitivity to HCQ or other 4-aminoquinoline compounds
Currently hospitalized
Symptomatic with subjective fever, cough, or sore throat
Current medications exclude concomitant use of HCQ
Concomitant use of other anti-malarial treatment or chemoprophylaxis
History of retinopathy of any etiology
Psoriasis
Porphyria
Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes < 1500) or thrombocytopenia (< 100 K)
Concomitant use of digoxin, cyclosporin, cimetidine, or tamoxifen
Known liver disease
Known long QT syndrome
Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of the study drugs, or planned use during the study period
Intervention: Hydroxychloroquine Sulfate
Trial phase: Phase 2
SMILES: CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: • Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days

Hydroxychloroquine Sulfate: Given PO
Eligibility criteria:
Inclusion Criteria:

Patients with proven SARS-CoV-2 infection by an accepted assay with symptoms consistent with COVID-19
Ability to measure and quantify viral load by quantitative PCR
Age 18 to 89
Ability to swallow oral medications
Patients must read, understand and sign IRB approved informed consent

Exclusion Criteria:

Pregnancy or women who are breast feeding
Two consecutive negative assays for SARS-CoV-2 infection
Patients that lack decision-making capacity will not be approached to participate in this study
Inability to tolerate oral medications
Allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate
QTc interval > 470 mSEC
History of ongoing ventricular cardiac dysrhythmias of grade 2 as described by NCI CTCAE 5.0 criteria
History of serious ventricular arrhythmia (VT or VF > 3 beats in a row)
Intervention: Sirolimus
Trial phase: Phase 2
ATC code: L01EG04 | L04AA10 | S01XA23
SMILES: COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Sirolimus 6mg on day 1 followed by 2mg daily for the next 13 days or until hospital discharge, whatever happens sooner.

Sirolimus: Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.
Eligibility criteria:
Inclusion Criteria:

Subjects enrolled in the trial must meet all of the following criteria.

Confirmed COVID-19 pneumonia
Hypoxia as defined by room air oxygen saturation less than 92% or supplemental oxygen requirement
Presence of at least one additional biomarker that has been shown to predict poor prognosis: a) serum ferritin ≥500ug/l, b) LDH ≥250U/L, c) d-dimer ≥1ug/L, or d) lymphopenia as defined by absolute lymphocyte count <1,000/uL
Age ≥ 18 years
Completed informed consent

Exclusion Criteria:

Subjects who meet ANY of the following criteria are not eligible for enrollment as study participants:

Known allergy or hypersensitivity to sirolimus
Inability or refusal to provide informed consent
Advanced respiratory support (high flow oxygen ≥ 15 L/min, CPAP, non-invasive or invasive mechanical ventilation)
Active enrollment in other interventional clinical drug trials. Co-enrollment in observational studies and biorepositories is allowed.
Pregnant women
Breast feeding
On chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. A list of these medications is provided in Section 12.3.4

Any clinically significant medical disease which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to):

History of liver cirrhosis
End stage renal disease or need for renal replacement therapy
Decompensated heart failure
Known active tuberculosis or history of incompletely treated tuberculosis
Uncontrolled systemic bacterial or fungal infections
Active viral infection other than COVID-19
Intervention: Hydroxychloroquine Sulfate
Trial phase: Phase 2
SMILES: CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 46
Group description: HCQ sulfate HCQ 400mg (2x 200mg tablets) by mouth 6-12 hours apart on day 1, followed by 3 weeks of weekly 400mg (2x 200mg tablets) by mouth

Hydroxychloroquine Sulfate (HCQ): Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
Eligibility criteria:
Inclusion Criteria:

Volunteers ages 18 to 99 years,
Able to sign own informed consent form,
Considered high-risk healthcare care providers in a hospital setting with active exposure to COVID-19 infection.

High-risk healthcare providers are defined as those actively working during the study duration in the Emergency Department and in the Intensive Care Setting, for the purpose of this study.

Exclusion Criteria:

Inability to tolerate an oral medication or known allergy to chloroquine or hydroxychloroquine
Pregnancy or breast-feeding
Immunocompromised status, hepatic failure, electrolytic imbalance
Creatinine clearance (CCL) <30 mL/min
Prolonged QT interval (QTc > 450ms for males and QTc > 470 for females)
Confirmed COVID-19 infection on baseline testing
Has another known contraindication to treatment with the study drug, including retinopathy.
Intervention: Fluorescein Sodium
Trial phase: Phase 2
SMILES: O=C([O-])c1ccccc1-c1c2ccc(=O)cc-2oc2cc([O-])ccc12.[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Subjects undergoing clinically planned vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma, removal surgery will have contrast agent fluorescein sodium administered intravenously after tumor exposure, and a special filter called YELLOW560 will be used on the operating microscope to see the fluorescent coloring of the contrast.

Fluorescein Sodium: Intravenous administration 1 mg/kg initial dosing if insufficient additional doses of 1 mg/kg may be administered.

YELLOW560 filter: Integrated fluorescence module serves to make fluorescent areas visible to assist in visualizing tumor during the resection.
Eligibility criteria:
Inclusion Criteria

Patient with a suspected VS
Recurrent VS with prior microsurgical resection or radiation therapy
Clinical indication for microsurgical resection

Exclusion Criteria

History of allergy to FS
History of renal failure
Pregnant women
Those with inability to give informed consent
Prisoners and inmates
Intervention: Water
Trial phase: Phase 2
SMILES: O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Over the counter: Distilled water
Eligibility criteria:
Inclusion Criteria:

Tested positive for COVID-19 with a sample collected in the prior 7 days
Ability to read and speak English or Spanish
Ability to participate in the study for 4 weeks
Being asymptomatic or having mild or moderate symptoms (for example, sore throat, coughing, fever, fatigue)
Ability to rinse/gargle
Not having any condition that might worsen with gargling solutions
Not having a history of mouthwash sensitivity
Not having an allergy to any mouthwash that has been used before
Not using another mouthwash/gargling solution since the most recent positive test
Not taking antimicrobial medications (antibacterial, antiviral, antibiotics including off-label FDA-approved medications such as hydroxychloroquine)
Anticipated ability to participate in the study for 4 weeks
Have a cellphone and agree to receive text messages for reminders to use mouthwash during the day and for follow-up visits, and can videoconference (like zoom) on a cellphone, tablet, or computer for sample collection instructions

Exclusion Criteria:

People who because of their symptoms intend to receive antiviral medications that could potentially affect viral load in their saliva samples
Pregnant or lactating women due to potential aversions to mouthwash solution taste/smell.
Intervention: RIFAMPIN
Trial phase: Phase 4
ATC code: J04AB02 | J04AM02 | J04AM05 | J04AM06 | J04AM07 | J04BA50 | J04BA51
SMILES: COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c(C=NN5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 24
Group description: Will receive 2 week regimen of rifampin 600mg per day

Rifampin 600 MG: Administered daily for 2 weeks
Eligibility criteria:
Inclusion Criteria:

Healthy women, who have had an ENG implant for 12-36 months at the time of enrollment and will maintain their implant during the study without modifications.

Exclusion Criteria:

o Women who are taking any known cytochrome P-450 3A4 enzyme inducers or inhibitors.

Women with a known allergy or insensitivity to rifampin.

Women with a body mass index (BMI) <18.5, as underweight women may have altered metabolism. The investigators will not have an upper BMI cut-off as studies have shown that overweight and obese women have equivalent metabolism and efficacy with the ENG contraceptive implant6,7.

• Exclusions Criteria (screening laboratory testing)

Women with any hepatic or renal dysfunction as determined by a comprehensive metabolic panel. For purposes of this study, liver function tests will be evaluated and evidence of hepatic dysfunction will be defined as an ALT >52 or AST >39, which are beyond the reference range of normal values used by the University of Colorado clinical laboratory. Renal function will be assessed by a serum creatinine and a value >1.2 will be evidence of renal dysfunction as this is greater than the reference range used by the University of Colorado clinical laboratory.
Women with any abnormal hematology as determined by a complete blood count. For purposes of this study, abnormal hematology will be defined as a WBC, RBC, or PLT value beyond the reference range of normal values used by the University of Colorado clinical laboratory.
Women with abnormal coagulation factors as determined by coagulation factor tests (PT/INR, PTT). For purposes of this study, abnormal coagulation factors will be defined as any test value beyond the reference range of normal values used by the University of Colorado clinical laboratory.
Intervention: Spironolactone
Trial phase: Phase 4
ATC code: C03DA01
SMILES: [H][C@]12CC[C@]3(C)[C@]4(CCC(=O)O4)CC[C@@]3([H])[C@]1([H])[C@]([H])(SC(C)=O)CC1=CC(=O)CC[C@@]12C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: Patients randomized to active therapy with spironolactone

spironolactone: aldosterone blocker
Eligibility criteria:
Inclusion Criteria:

-Patients were considered eligible for enrollment only if they had received

an ICD therapy, either a shock or antitachycardia pacing (ATP),
VT/VF in the previous 2 years or
received an ICD for secondary prevention of sustained VT/VF in the previous 6 months.

Exclusion Criteria:

-Important exclusion criteria were

an indication for spironolactone based on the RALES trial (EF of <35% and -New York Heart Association (NYHA) class III or IV),
unstable angina,
primary hepatic failure,
known intolerance to spironolactone,
a serum creatinine concentration of >2.5 mg/dL,
a serum potassium concentration of >5.0 mmol/L, and
a life expectancy of <2 years.